DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gf3vrn/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Affimed Therapeutics AG
- Chipscreen Biosciences Ltd
- Cornerstone Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Galderma S.A.
- Innate Pharma SA
- Johnson & Johnson
- Karyopharm Therapeutics, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- MedImmune, LLC
- Neumedicines Inc.
- Novartis AG
- OncoSec Medical Inc.
- Onyx Pharmaceuticals, Inc.
- Soligenix, Inc.
Taiwan Liposome Company, Ltd.
For more information visit http://www.researchandmarkets.com/research/gf3vrn/cutaneous_tcell